

An abstract, colorful representation of a protein structure, featuring various loops and beta-sheets in shades of yellow, green, blue, and red, set against a dark blue background with a subtle light pattern.

BIPHARMACEUTICALS

BIOCHEMISTRY AND BIOTECHNOLOGY

Second Edition

GARY WALSH

 WILEY



Contents

Preface

xvii

Chapter 1 Pharmaceuticals, biologics and biopharmaceuticals	1
Introduction to pharmaceutical products	1
Biopharmaceuticals and pharmaceutical biotechnology	1
History of the pharmaceutical industry	3
The age of biopharmaceuticals	5
Biopharmaceuticals: current status and future prospects	8
Traditional pharmaceuticals of biological origin	12
Pharmaceuticals of animal origin	13
The sex hormones	14
The androgens	14
Oestrogens	15
Progesterone and progestogens	17
Corticosteroids	19
Catecholamines	21
Prostaglandins	23
Pharmaceutical substances of plant origin	27
Alkaloids	28
Atropine and scopolamine	28
Morphine and cocaine	29
Additional plant alkaloids	30
Ergot alkaloids	30
Flavonoids, xanthines and terpenoids	30
Cardiac glycosides and coumarins	33
Aspirin	33
Pharmaceutical substances of microbial origin	33
The macrolides and ansamycins	38
Peptide and other antibiotics	39
Conclusion	39
Further reading	40
Chapter 2 The drug development process	43
Drug discovery	44
The impact of genomics and related technologies upon drug discovery	45

Gene chips	47
Proteomics	49
Structural genomics	50
Pharmacogenetics	51
Plants as a source of drugs	52
Microbial drugs	53
Rational drug design	54
Combinatorial approaches to drug discovery	56
Initial product characterization	57
Patenting	57
What is a patent and what is patentable?	57
Patent types	62
The patent application	63
Patenting in biotechnology	64
Delivery of biopharmaceuticals	66
Oral delivery systems	66
Pulmonary delivery	67
Nasal, transmucosal and transdermal delivery systems	68
Pre-clinical trials	69
Pharmacokinetics and pharmacodynamics	69
Toxicity studies	71
Reproductive toxicity and teratogenicity	71
Mutagenicity, carcinogenicity and other tests	72
Clinical trials	73
Clinical trial design	75
Trial size and study population	75
Randomized control studies	76
Additional trial designs	76
The role and remit of regulatory authorities	78
The Food and Drug Administration	78
The investigational new drug application	80
The new drug application	82
European regulations	84
National regulatory authorities	84
The EMEA and the new EU drug approval systems	85
The centralized procedure	86
Mutual recognition	88
Drug registration in Japan	88
World harmonization of drug approvals	89
Conclusion	89
Further reading	89
Chapter 3 The drug manufacturing process	93
International pharmacopoeia	93
<i>Martindale, the Extra Pharmacopoeia</i>	94
Guides to good manufacturing practice	94

The manufacturing facility	97
Clean rooms	98
Cleaning, decontamination and sanitation (CDS)	101
CDS of the general manufacturing area	102
CDS of process equipment	102
Water for biopharmaceutical processing	104
Generation of purified water and water for injections (WFI)	105
Distribution system for WFI	107
Documentation	109
Specifications	110
Manufacturing formulae, processing and packaging instructions	110
Records	111
Generation of manufacturing records	111
Sources of biopharmaceuticals	112
<i>E. coli</i> as a source of recombinant, therapeutic proteins	112
Expression of recombinant proteins in animal cell culture systems	116
Additional production systems: yeasts	116
Fungal production systems	117
Transgenic animals	118
Transgenic plants	122
Insect cell-based systems	123
Production of final product	124
Cell banking systems	127
Upstream processing	128
Microbial cell fermentation	129
Mammalian cell culture systems	133
Downstream processing	134
Final product formulation	140
Some influences that can alter the biological activity of proteins	142
Proteolytic degradation	143
Protein deamidation	144
Oxidation and disulphide exchange	145
Alteration of glycoprotein glycosylation patterns	147
Stabilizing excipients used in final product formulations	150
Final product fill	153
Freeze-drying	155
Labelling and packing	158
Analysis of the final product	159
Protein-based contaminants	159
Removal of altered forms of the protein of interest from the product stream	160
Product potency	161
Determination of protein concentration	163
Detection of protein-based product impurities	164
Capillary electrophoresis	166
High-pressure liquid chromatography (HPLC)	167
Mass spectrometry	168
Immunological approaches to detection of contaminants	168

Amino acid analysis	169
Peptide mapping	170
N-terminal sequencing	171
Analysis of secondary and tertiary structure	173
Endotoxin and other pyrogenic contaminants	173
Endotoxin, the molecule	174
Pyrogen detection	176
DNA	179
Microbial and viral contaminants	180
Viral assays	181
Miscellaneous contaminants	182
Validation studies	183
Further reading	185

Chapter 4 The cytokines — the interferon family 189

Cytokines	189
Cytokine receptors	194
Cytokines as biopharmaceuticals	195
The interferons	196
The biochemistry of interferon- α	197
Interferon- β	198
Interferon- γ	198
Interferon signal transduction	198
The interferon receptors	199
The JAK-STAT pathway	199
The interferon JAK-STAT pathway	202
The biological effects of interferons	203
The eIF-2 α protein kinase system	207
Interferon biotechnology	207
Production and medical uses of IFN- α	210
Medical uses of IFN- β	213
Medical applications of IFN- γ	214
Interferon toxicity	216
Additional interferons	218
Conclusion	219
Further reading	219

Chapter 5 Cytokines: interleukins and tumour necrosis factor 223

Interleukin-2 (IL-2)	225
IL-2 production	228
IL-2 and cancer treatment	228
IL-2 and infectious diseases	230
Safety issues	231
Inhibition of IL-2 activity	231

Interleukin-1 (IL-1)	232
The biological activities of IL-1	233
IL-1 biotechnology	234
Interleukin-3: biochemistry and biotechnology	235
Interleukin-4	236
Interleukin-6	238
Interleukin-11	240
Interleukin-5	241
Interleukin-12	244
Tumour necrosis factors (TNFs)	246
TNF biochemistry	246
Biological activities of TNF- α	247
Immunity and inflammation	248
TNF receptors	249
TNF: therapeutic aspects	250
Further reading	252
 Chapter 6 Haemopoietic growth factors	 255
The interleukins as haemopoietic growth factors	257
Granulocyte colony stimulating factor (G-CSF)	258
Macrophage colony-stimulating factor (M-CSF)	259
Granulocyte-macrophage colony stimulating factor (GM-CSF)	259
Clinical application of CSFs	261
Leukaemia inhibitory factor (LIF)	263
Erythropoietin (EPO)	264
The EPO receptor and signal transduction	267
Regulation of EPO production	267
Therapeutic applications of EPO	268
Chronic disease and cancer chemotherapy	271
Additional non-renal applications	272
Tolerability	273
Thrombopoietin	273
Further reading	275
 Chapter 7 Growth factors	 277
Growth factors and wound healing	277
Insulin-like growth factors (IGFs)	279
IGF biochemistry	280
IGF receptors	280
IGF-binding proteins	282
Biological effects	282
IGF and fetal development	283
IGFs and growth	283
Renal and reproductive effects	284
Neuronal and other effects	285

Epidermal growth factor (EGF)	285
The EGF receptor	286
Platelet-derived growth factor (PDGF)	287
The PDGF receptor and signal transduction	288
PDGF and wound healing	289
Fibroblast growth factors (FGFs)	289
Transforming growth factors (TGFs)	290
TGF- α	290
TGF- β	292
Neurotrophic factors	293
The neurotrophins	294
Neurotrophin receptors	296
The neurotrophin low-affinity receptor	297
Ciliary neurotrophic factor and glial cell line-derived neurotrophic factor	297
Neurotrophic factors and neurodegenerative disease	298
Amyotrophic lateral sclerosis (ALS) and peripheral neuropathy	298
Neurotrophic factors and neurodegenerative diseases of the brain	298
Further reading	300
Chapter 8 Hormones of therapeutic interest	303
Insulin	303
Diabetes mellitus	304
The insulin molecule	304
The insulin receptor and signal transduction	307
Insulin production	307
Enzymatic conversion of porcine insulin	311
Production of human insulin by recombinant DNA technology	312
Formulation of insulin products	314
Engineered insulins	317
Additional means of insulin administration	320
Treating diabetics with insulin-producing cells	321
Glucagon	321
Human growth hormone (hGH)	324
Growth hormone releasing factor (GHRF) and inhibitory factor (GHRIF)	325
The GH receptor	325
Biological effects of GH	327
Therapeutic uses of GH	328
Recombinant hGH (rhGH) and pituitary dwarfism	328
Idiopathic short stature and Turner's syndrome	330
Metabolic effects of hGH	330
GH, lactation and ovulation	331
The gonadotrophins	331
Follicle stimulating hormone (FSH), luteinizing hormone (LH)	
and human chorionic gonadotrophin (hCG)	331
Pregnant mare serum gonadotrophin (PMSG)	335
The inhibins and activins	337

LHRH and regulation of gonadotrophin production	338
Medical and veterinary applications of gonadotrophins	339
Sources and medical uses of FSH, LH and hCG	340
Recombinant gonadotrophins	342
Veterinary uses of gonadotrophins	344
Gonadotrophin releasing hormone (GnRH)	345
Additional recombinant hormones now approved	345
Conclusions	348
Further reading	348
 Chapter 9 Blood products and therapeutic enzymes	 351
Disease transmission	351
Whole blood	353
Platelets and red blood cells	353
Blood substitutes	353
Dextrans	354
Albumin	355
Gelatin	357
Oxygen-carrying blood substitutes	357
Haemostasis	358
The coagulation pathway	358
Terminal steps of coagulation pathway	361
Clotting disorders	365
Factor VIII and haemophilia	366
Production of factor VIII	368
Factors IX, VII _a and XIII	371
Anticoagulants	372
Heparin	372
Vitamin K antimetabolites	375
Hirudin	375
Antithrombin	379
Thrombolytic agents	380
Tissue plasminogen activator (tPA)	381
First-generation tPA	383
Engineered tPA	383
Streptokinase	385
Urokinase	386
Staphylokinase	386
α_1 -Antitrypsin	388
Enzymes of therapeutic value	389
Asparaginase	390
DNase	392
Glucocerebrosidase	393
α -Galactosidase and urate oxidase	395
Superoxide dismutase	397

Debriding agents	397
Digestive aids	398
Lactase	400
Further reading	400
Chapter 10 Antibodies, vaccines and adjuvants	403
Polyclonal antibody preparations	403
Anti-D immunoglobulin	406
Normal immunoglobulins	407
Hepatitis B and tetanus immunoglobulin	407
Snake and spider antivenins	408
Monoclonal antibodies	409
Production of monoclonals via hybridoma technology	411
Antibody screening: phage display technology	412
Therapeutic application of monoclonal antibodies	414
Tumour immunology	415
Antibody-based strategies for tumour detection/destruction	417
Drug-based tumour immunotherapy	424
First-generation anti-tumour antibodies: clinical disappointment	426
Tumour-associated antigens	426
Antigenicity of murine monoclonals	428
Chimaeric and humanized antibodies	429
Antibody fragments	432
Additional therapeutic applications of monoclonal antibodies	433
Cardiovascular and related disease	433
Infectious diseases	433
Autoimmune disease	434
Transplantation	434
Vaccine technology	435
Traditional vaccine preparations	436
Attenuated, dead or inactivated bacteria	438
Attenuated and inactivated viral vaccines	439
Toxoids, antigen-based and other vaccine preparations	440
The impact of genetic engineering on vaccine technology	441
Peptide vaccines	444
Vaccine vectors	445
Development of an AIDS vaccine	447
Difficulties associated with vaccine development	450
AIDS vaccines in clinical trials	450
Cancer vaccines	452
Recombinant veterinary vaccines	452
Adjuvant technology	453
Adjuvant mode of action	455
Mineral-based adjuvants	455
Oil-based emulsion adjuvants	455

Bacteria/bacterial products as adjuvants	457
Additional adjuvants	458
Further reading	460
Chapter 11 Nucleic acid therapeutics	463
Gene therapy	463
Basic approach to gene therapy	464
Some additional questions	467
Vectors used in gene therapy	468
Retroviral vectors	468
Additional viral-based vectors	472
Manufacture of viral vectors	474
Non-viral vectors	476
Manufacture of plasmid DNA	480
Gene therapy and genetic disease	482
Gene therapy and cancer	485
Gene therapy and AIDS	486
Gene-based vaccines	488
Gene therapy: some additional considerations	488
Anti-sense technology	488
Anti-sense oligonucleotides	490
Uses, advantages and disadvantages of 'oligos'	491
Delivery and cellular uptake of oligonucleotides	493
Manufacture of oligonucleotides	493
Vitravene, an approved antisense agent	494
Antigene sequences and ribozymes	494
Conclusion	495
Further reading	496
Appendix 1 Biopharmaceuticals thus far approved in the USA or European Union	499
Appendix 2 Some Internet addresses relevant to the biopharmaceutical sector	509
Appendix 3 Two selected monographs reproduced from the <i>European Pharmacopoeia</i> with permission from the European Commission:	
I. Products of recombinant DNA technology	515
II. Interferon α -2 concentrated solution	520
Appendix 4 Manufacture of biological medicinal products for human use. (Annex 2 from <i>The Rules Governing Medicinal Products in the European Community, Vol. 4, Good Manufacturing Practice for Medicinal Products</i>)	527
Index	533